CXCR4 antagonists dramatically reduce AML load in mice previously engrafted with primary human AML without influencing the engraftment of normal hematopoietic progenitors (128), probably because tumor cells express higher levels of CXCR4 than normal cells (125). Here, CXCR4 is linked to acute myeloid leukemia.